Please sign in to follow a disease.
Brain pacemaker tested for untreatable schizophrenia
NCT ID NCT02361554
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested deep brain stimulation (DBS) in 15 people with treatment-resistant schizophrenia who still had severe hallucinations despite medication. The device was placed in a brain area linked to schizophrenia to try to calm symptoms. The study was terminated early, so we don't have clear results on whether it worked.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Deep brain stimulation device (Medtronic Percept with SensSight)
- What this could lead to
- If successful, this could offer a new option for people with severe schizophrenia who don't respond to medication, potentially reducing hallucinations and improving daily function.
- What could go wrong
- This was a very small, early pilot study that was terminated, so results are limited. Deep brain stimulation is invasive brain surgery and carries risks like infection, bleeding, or device-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males and females who are at least 22 years of age. * Subject has a diagnosis of schizophrenia or schizoaffective disorder as determined by a review of medical records, discussion with referring psychiatrist as well as the Structured Clinical Interview for DSM-V (SCID-V). * Subject determined to be treatment-resistant for at least one year prior to the Screening Visit as demonstrated by clinical evidence (determined by review of medical records and discussion with referring psychiatrist) of persistent auditory hallucinations and/or delusions that have not responded to treatment with three adequate regimens of antipsychotic medication including one failed trial of clozapine as defined as follows: 1. Adequate trials of two different antipsychotic drugs (not including clozapine) belonging to different classes of at least 12 weeks equivalent to at least 500 mg/day of chlorpromazine within the previous 5 years. 2. A trial of clozapine of at least12 weeks at a dose of at least 400 mg (or a clozapine level of at least 350 ng/mL). Subjects who were unable to tolerate clozapine at this dose or for this duration because of intolerable side effects are also eligible. * Subject has at least a score of 6 (severe) on 2 of the 4 BPRS positive symptoms (conceptual disorganization, grandiosity, hallucinatory behavior and unusual thought content) at all three Baseline Visits prior to undergoing surgery. One of the 2 must be hallucinatory behavior. * Subject must be ambulatory. * Females who are postmenopausal, physically incapable of childbearing, or practicing an acceptable method of birth control. Acceptable methods of birth control include surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or diaphragm with a spermicidal agent or intrauterine device \[IUD\]). If practicing an acceptable method of birth control, a negative urine pregnancy test result has been obtained at baseline Visits 1 and 3. * Subject is determined by independent psychiatrist with expertise in capacity assessments to have decision-making capacity to provide informed consent. * Subject is able to read English, understand and cooperate with study procedures, and has signed a written informed consent form prior to any study procedures. Exclusion Criteria: * Subject has a positive urine drug screen at any of the three Baseline Visits. * Subject had major surgery within three months prior to Baseline Visit 1 or has other surgery planned during the proposed study period. * Subject is determined by medical consultant to have medical contraindications to undergoing surgery. * Subject is pregnant or breast-feeding. * Subject has a history of alcohol or drug abuse within the past 6 months and dependence within the past year. * Subject has a medical illness/condition, co-morbid psychiatric illness, and/or abnormal diagnostic finding that would interfere with the completion of the study, confound the results of the study, or pose risk to the patient. * Subject has participated in another investigational drug trial or therapeutic trial within 30 days of Baseline Visit 1. * Subject has a diagnosis of mental retardation. * Subject has a neurological condition, or a history of traumatic brain injury associated with loss of consciousness of \> 1 hour and/or intracranial/epidural/subdural bleeding. * Subject has defibrillator or pacemaker or other implants that will interfere with MRI and functioning of the device. * Unstable psycho-social condition including housing and poor support.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Treatment resistant schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping the brain at the moment voices start
- Desert plant tested against Clozapine's weighty side effects
- Can a targeted electric field reach deep brain to quiet schizophrenia symptoms?
- Could a common food preservative help treat Hard-to-Treat schizophrenia?
- Brain pacemaker trial aims to quiet voices in Treatment-Resistant schizophrenia
- Old drug, new hope: could acetazolamide ease tough schizophrenia symptoms?